The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities.
 
Bilal A. Siddiqui
No Relationships to Disclose
 
Jean-Bernard Durand
Consulting or Advisory Role - Novartis
 
Jianjun Gao
Travel, Accommodations, Expenses - AstraZeneca
 
Jianbo Wang
No Relationships to Disclose
 
Ana Aparicio
Honoraria - Biosense Webster (I); Boston Scientific (I); Genzyme
Consulting or Advisory Role - American Cancer Society; American Cancer Society; Biosense Webster (I); Boston Scientific (I); Bristol-Myers Squibb; GlaxoSmithKline; Janssen Research & Development
Speakers' Bureau - Biosense Webster (I); Boston Scientific (I)
Research Funding - BioSense Webster (I); Boston Scientific (I); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Hansen Medical (I); Janssen (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Two (I)
Travel, Accommodations, Expenses - Biosense WEbster (I)
 
Matthew T Campbell
Honoraria - Eisai; EMD Serono; Genentech/Roche; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Novartis; Pfizer
Research Funding - Exelixis
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Genentech; Inovio Pharmaceuticals; Janssen; Lilly; Merck; NCCN; Nektar; Seagen
Research Funding - BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Oncorena; Ono Pharmaceutical; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer
 
Paul Gettys Corn
Research Funding - Exelixis (Inst); Sanofi (Inst)
 
Pavlos Msaouel
Research Funding - Bristol-Myers Squibb (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
Amado J. Zurita
Honoraria - Exelixis; Janssen Oncology
Consulting or Advisory Role - Exelixis
Research Funding - Infinity Pharmaceuticals; Pfizer
 
Shi-Ming Tu
No Relationships to Disclose
 
Maria E. Suarez-Almazor
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Pfizer
Research Funding - Pfizer
 
Tummala Sudhakar
No Relationships to Disclose
 
Christopher Logothetis
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Sanofi
Research Funding - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Novartis; Sanofi
 
Padmanee Sharma
Stock and Other Ownership Interests - Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Forty Seven; Forty Seven (I); Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Jounce Therapeutics; Jounce Therapeutics (I); Marker Therapeutics; Marker Therapeutics (I); Neon Therapeutics; Neon Therapeutics (I); Oncolytics; Polaris; Polaris (I); TapImmune Inc.; TapImmune Inc. (I); Tvardi Therapeutics (I)
Consulting or Advisory Role - Amgen (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); Bristol-Myers Squibb (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Forty Seven; Forty Seven (I); Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Jounce Therapeutics; Jounce Therapeutics (I); Marker Therapeutics; Marker Therapeutics (I); Merck; Merck (I); Neon Therapeutics; Neon Therapeutics (I); Oncolytics; Pieris Pharmaceuticals; Polaris; Polaris (I); TapImmune Inc.; TapImmune Inc. (I); Tvardi Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Sumit Kumar Subudhi
Honoraria - Apricity Health; Compugen; Dendreon; Janssen
Consulting or Advisory Role - Apricity Health; Dendreon; Janssen; Polaris; Valeant/Dendreon
Travel, Accommodations, Expenses - Compugen; Dendreon; Janssen